Prostate cancer vaccine safety and effectiveness study
Part of Cancer clinical trials.
This trial tests a prostate cancer vaccine made from your own immune cells. It aims to see if the vaccine is safe and can help your body fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer that is a type called adenocarcinoma.
- You should be able to care for yourself and be up and about (ECOG 0 or 1).
- Your blood counts, kidney function, and liver function need to be within certain ranges.
- You cannot have an active infection, autoimmune disease, or HIV/hepatitis B or C.
- You must be willing to give blood samples and have a procedure called leukapheresis to collect cells for the vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help your body fight advanced cancer. It is for people whose cancer has not responded to other treatments.
This trial tests a new vaccine (TriAdeno) combined with an immune-boosting drug to help your body fight early-stage prostate cancer while you're on active surveillance—a watchful waiting approach. The vaccine may help prevent cancer growth without surgery or radiation.
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
This trial tests a personalized cancer vaccine (YS247) designed to train your immune system to recognize and fight your prostate cancer. It may help slow or stop cancer growth in men whose cancer has spread and stopped responding to standard hormone treatments.
This trial tests a personalized vaccine (FK-PC101) given after prostate removal surgery for men with high-risk prostate cancer. It aims to see if the vaccine can help prevent the cancer from coming back without the need for additional hormone therapy or radiation.
This trial tests a drug called IL-15 superagonist (with or without a vaccine) for men whose prostate cancer has come back (shown by rising PSA) after they already had targeted radiation therapy. The goal is to see if this treatment can lower or control PSA levels.
Hear when a new Prostate Cancer Indications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.